| # | Pathway | Proteins |
|---|
| 1 | Dilated cardiomyopathy | ENSAPLP00000015089, ENSAPLP00000012522, ENSAPLP00000016135, ENSAPLP00000009011, ENSAPLP00000011291, ENSAPLP00000003657, ENSAPLP00000011738, ENSAPLP00000012136, ENSAPLP00000003219, ENSAPLP00000016219, ENSAPLP00000009880 |
| 2 | Hypertrophic cardiomyopathy (HCM) | ENSAPLP00000015089, ENSAPLP00000012522, ENSAPLP00000009011, ENSAPLP00000003657, ENSAPLP00000011738, ENSAPLP00000012136, ENSAPLP00000003219, ENSAPLP00000016219, ENSAPLP00000009880 |
| 3 | Focal adhesion | ENSAPLP00000014466, ENSAPLP00000008118, ENSAPLP00000010282, ENSAPLP00000009011, ENSAPLP00000013787, ENSAPLP00000003837, ENSAPLP00000005411, ENSAPLP00000013019, ENSAPLP00000011738, ENSAPLP00000009311, ENSAPLP00000012559, ENSAPLP00000014622, ENSAPLP00000016096, ENSAPLP00000009880, ENSAPLP00000013090 |
| 4 | ECM-receptor interaction | ENSAPLP00000014466, ENSAPLP00000008118, ENSAPLP00000009011, ENSAPLP00000013787, ENSAPLP00000011738, ENSAPLP00000012559, ENSAPLP00000004826, ENSAPLP00000014622, ENSAPLP00000016096 |
| 5 | Amoebiasis | ENSAPLP00000012216, ENSAPLP00000016135, ENSAPLP00000008118, ENSAPLP00000011291, ENSAPLP00000013019, ENSAPLP00000011738, ENSAPLP00000012559, ENSAPLP00000014622, ENSAPLP00000004050 |
| 6 | Malaria | ENSAPLP00000016307, ENSAPLP00000007488, ENSAPLP00000005443, ENSAPLP00000011743 |
| 7 | Ribosome | ENSAPLP00000010767, ENSAPLP00000007657, ENSAPLP00000012634, ENSAPLP00000008212, ENSAPLP00000014148, ENSAPLP00000005418, ENSAPLP00000015793, ENSAPLP00000004439, ENSAPLP00000003372, ENSAPLP00000010726, ENSAPLP00000008154 |
| 8 | African trypanosomiasis | ENSAPLP00000016307, ENSAPLP00000011291, ENSAPLP00000007488, ENSAPLP00000005443 |
| 9 | Tight junction | ENSAPLP00000010282, ENSAPLP00000013019, ENSAPLP00000015489, ENSAPLP00000007172, ENSAPLP00000012466, ENSAPLP00000005955, ENSAPLP00000006991, ENSAPLP00000009880, ENSAPLP00000013090 |
| 10 | Vascular smooth muscle contraction | ENSAPLP00000016135, ENSAPLP00000005411, ENSAPLP00000015489, ENSAPLP00000005955, ENSAPLP00000006991, ENSAPLP00000002381, ENSAPLP00000013090 |
| 11 | PI3K-Akt signaling pathway | ENSAPLP00000002091, ENSAPLP00000014466, ENSAPLP00000008118, ENSAPLP00000009011, ENSAPLP00000011291, ENSAPLP00000013787, ENSAPLP00000011738, ENSAPLP00000004439, ENSAPLP00000012559, ENSAPLP00000014548, ENSAPLP00000014622, ENSAPLP00000016096 |
| 12 | Proteoglycans in cancer | ENSAPLP00000003286, ENSAPLP00000016135, ENSAPLP00000013972, ENSAPLP00000013787, ENSAPLP00000003837, ENSAPLP00000004439, ENSAPLP00000013387, ENSAPLP00000009311, ENSAPLP00000012559, ENSAPLP00000004826, ENSAPLP00000009880 |
| 13 | Salmonella infection | ENSAPLP00000003837, ENSAPLP00000015489, ENSAPLP00000009311, ENSAPLP00000005955, ENSAPLP00000006991, ENSAPLP00000009880 |
| 14 | Estrogen signaling pathway | ENSAPLP00000003286, ENSAPLP00000016135, ENSAPLP00000000447, ENSAPLP00000013972, ENSAPLP00000013387, ENSAPLP00000014548 |
| 15 | Protein digestion and absorption | ENSAPLP00000008118, ENSAPLP00000008210, ENSAPLP00000012993, ENSAPLP00000014622, ENSAPLP00000016096 |
| 16 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ENSAPLP00000012522, ENSAPLP00000009011, ENSAPLP00000013019, ENSAPLP00000011738, ENSAPLP00000016219, ENSAPLP00000009880 |
| 17 | Bladder cancer | ENSAPLP00000003286, ENSAPLP00000013972, ENSAPLP00000013387 |
| 18 | Leukocyte transendothelial migration | ENSAPLP00000003286, ENSAPLP00000010282, ENSAPLP00000013972, ENSAPLP00000013019, ENSAPLP00000013387, ENSAPLP00000009880, ENSAPLP00000013090 |
| 19 | Endocrine and other factor-regulated calcium reabsorption | ENSAPLP00000016135, ENSAPLP00000005099, ENSAPLP00000016247, ENSAPLP00000006303 |
| 20 | Regulation of actin cytoskeleton | ENSAPLP00000010282, ENSAPLP00000009011, ENSAPLP00000005411, ENSAPLP00000013019, ENSAPLP00000015489, ENSAPLP00000012559, ENSAPLP00000005955, ENSAPLP00000006991, ENSAPLP00000009880, ENSAPLP00000013090 |
| 21 | Sphingolipid metabolism | ENSAPLP00000000648, ENSAPLP00000007794 |
| 22 | Cardiac muscle contraction | ENSAPLP00000015089, ENSAPLP00000003657, ENSAPLP00000012136, ENSAPLP00000003219 |
| 23 | Viral myocarditis | ENSAPLP00000011291, ENSAPLP00000011738, ENSAPLP00000016219, ENSAPLP00000009880 |
| 24 | Tyrosine metabolism | ENSAPLP00000005038, ENSAPLP00000012915, ENSAPLP00000004066 |
| 25 | Gastric acid secretion | ENSAPLP00000016135, ENSAPLP00000005411, ENSAPLP00000002717, ENSAPLP00000009880 |
| 26 | Phenylalanine metabolism | ENSAPLP00000005038, ENSAPLP00000004066 |
| 27 | Hippo signaling pathway - fly | ENSAPLP00000002091, ENSAPLP00000003083, ENSAPLP00000012596, ENSAPLP00000009880 |
| 28 | Platelet activation | ENSAPLP00000004094, ENSAPLP00000016135, ENSAPLP00000010282, ENSAPLP00000005411, ENSAPLP00000004030, ENSAPLP00000009880 |
| 29 | Small cell lung cancer | ENSAPLP00000008118, ENSAPLP00000011738, ENSAPLP00000012559, ENSAPLP00000014622 |
| 30 | Adrenergic signaling in cardiomyocytes | ENSAPLP00000015089, ENSAPLP00000016135, ENSAPLP00000003657, ENSAPLP00000012136, ENSAPLP00000003219 |
| 31 | Cocaine addiction | ENSAPLP00000016135, ENSAPLP00000012915 |
| 32 | Vitamin digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561 |
| 33 | Pathways in cancer | ENSAPLP00000003286, ENSAPLP00000015089, ENSAPLP00000016135, ENSAPLP00000008118, ENSAPLP00000013972, ENSAPLP00000011738, ENSAPLP00000013387, ENSAPLP00000012559, ENSAPLP00000014548, ENSAPLP00000014622 |
| 34 | Bile secretion | ENSAPLP00000016135, ENSAPLP00000002717 |
| 35 | Regulation of lipolysis in adipocytes | ENSAPLP00000005715, ENSAPLP00000016135 |
| 36 | Fat digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561 |
| 37 | Systemic lupus erythematosus | ENSAPLP00000011291, ENSAPLP00000001762, ENSAPLP00000001720, ENSAPLP00000013019 |
| 38 | Transcriptional misregulation in cancer | ENSAPLP00000011291, ENSAPLP00000001762, ENSAPLP00000013972 |
| 39 | Thyroid hormone synthesis | ENSAPLP00000016135, ENSAPLP00000001822, ENSAPLP00000014548 |
| 40 | Synaptic vesicle cycle | ENSAPLP00000005099, ENSAPLP00000016247, ENSAPLP00000006303 |
| 41 | Pathogenic Escherichia coli infection | ENSAPLP00000002091, ENSAPLP00000011602, ENSAPLP00000009880, ENSAPLP00000007755 |
| 42 | Glycosphingolipid biosynthesis - ganglio series | ENSAPLP00000000648 |
| 43 | Alcoholism | ENSAPLP00000016135, ENSAPLP00000001762, ENSAPLP00000001720, ENSAPLP00000012915 |
| 44 | Amphetamine addiction | ENSAPLP00000016135, ENSAPLP00000012915 |
| 45 | GnRH signaling pathway | ENSAPLP00000003286, ENSAPLP00000016135, ENSAPLP00000013387 |
| 46 | Epstein-Barr virus infection | ENSAPLP00000002091, ENSAPLP00000013416, ENSAPLP00000016135, ENSAPLP00000000447, ENSAPLP00000011291, ENSAPLP00000004050 |
| 47 | MAPK signaling pathway | ENSAPLP00000016135, ENSAPLP00000000447, ENSAPLP00000003837, ENSAPLP00000009311, ENSAPLP00000004050 |
| 48 | Asthma | ENSAPLP00000011291 |
| 49 | Oxytocin signaling pathway | ENSAPLP00000016135, ENSAPLP00000005411, ENSAPLP00000009880, ENSAPLP00000013090 |
| 50 | Glucagon signaling pathway | ENSAPLP00000016135, ENSAPLP00000005784, ENSAPLP00000010189 |
| 51 | Staphylococcus aureus infection | ENSAPLP00000004094, ENSAPLP00000011291 |
| 52 | Insulin signaling pathway | ENSAPLP00000003052, ENSAPLP00000016135, ENSAPLP00000004439, ENSAPLP00000010189 |
| 53 | Lysosome | ENSAPLP00000000648, ENSAPLP00000005099, ENSAPLP00000007794, ENSAPLP00000006338, ENSAPLP00000014590 |
| 54 | Gap junction | ENSAPLP00000016135, ENSAPLP00000011602, ENSAPLP00000007755 |
| 55 | Legionellosis | ENSAPLP00000000447, ENSAPLP00000009308 |
| 56 | Nitrogen metabolism | ENSAPLP00000002717 |
| 57 | Taste transduction | ENSAPLP00000016135 |
| 58 | Oocyte meiosis | ENSAPLP00000002091, ENSAPLP00000016135, ENSAPLP00000008934 |
| 59 | Progesterone-mediated oocyte maturation | ENSAPLP00000016135, ENSAPLP00000008934 |
| 60 | Vasopressin-regulated water reabsorption | ENSAPLP00000016135, ENSAPLP00000010780 |
| 61 | Amyotrophic lateral sclerosis (ALS) | ENSAPLP00000001822, ENSAPLP00000012498 |
| 62 | Viral carcinogenesis | ENSAPLP00000002091, ENSAPLP00000016135, ENSAPLP00000003083, ENSAPLP00000001720, ENSAPLP00000013019 |
| 63 | Complement and coagulation cascades | ENSAPLP00000004094, ENSAPLP00000004030, ENSAPLP00000006069 |
| 64 | Allograft rejection | ENSAPLP00000011291 |
| 65 | Endocytosis | ENSAPLP00000000447, ENSAPLP00000005099, ENSAPLP00000016247, ENSAPLP00000006303, ENSAPLP00000010780, ENSAPLP00000003542, ENSAPLP00000016193, ENSAPLP00000011749 |
| 66 | Hepatitis B | ENSAPLP00000002091, ENSAPLP00000013972, ENSAPLP00000004826 |
| 67 | Hippo signaling pathway | ENSAPLP00000002091, ENSAPLP00000003083, ENSAPLP00000009880 |
| 68 | HIF-1 signaling pathway | ENSAPLP00000015679, ENSAPLP00000004439, ENSAPLP00000005784 |
| 69 | Adherens junction | ENSAPLP00000003052, ENSAPLP00000013019, ENSAPLP00000009880 |
| 70 | Hedgehog signaling pathway | ENSAPLP00000016135 |
| 71 | Intestinal immune network for IgA production | ENSAPLP00000011291 |
| 72 | Proximal tubule bicarbonate reclamation | ENSAPLP00000002717 |
| 73 | Influenza A | ENSAPLP00000003661, ENSAPLP00000000447, ENSAPLP00000009880 |
| 74 | Ribosome biogenesis in eukaryotes | ENSAPLP00000013416, ENSAPLP00000006775 |
| 75 | Vibrio cholerae infection | ENSAPLP00000016135, ENSAPLP00000009880 |
| 76 | Measles | ENSAPLP00000000447, ENSAPLP00000011291 |
| 77 | Calcium signaling pathway | ENSAPLP00000016135, ENSAPLP00000011291, ENSAPLP00000005411 |
| 78 | Primary immunodeficiency | ENSAPLP00000011291 |
| 79 | Collecting duct acid secretion | ENSAPLP00000002717 |
| 80 | Autoimmune thyroid disease | ENSAPLP00000011291 |
| 81 | Phototransduction - fly | ENSAPLP00000009880 |
| 82 | PPAR signaling pathway | ENSAPLP00000005715, ENSAPLP00000003052 |
| 83 | Spliceosome | ENSAPLP00000003661, ENSAPLP00000005529, ENSAPLP00000000447, ENSAPLP00000014331, ENSAPLP00000012068 |
| 84 | Glycosaminoglycan degradation | ENSAPLP00000000648 |
| 85 | Thyroid cancer | ENSAPLP00000015089 |
| 86 | Other glycan degradation (no map in kegg database) | ENSAPLP00000000648 |
| 87 | Prion diseases | ENSAPLP00000016135, ENSAPLP00000000447 |
| 88 | Phagosome | ENSAPLP00000011602, ENSAPLP00000011291, ENSAPLP00000009880, ENSAPLP00000007755 |
| 89 | DNA replication | ENSAPLP00000008934 |
| 90 | Cell cycle | ENSAPLP00000002091, ENSAPLP00000008934 |
| 91 | Huntington's disease | ENSAPLP00000009300, ENSAPLP00000005099, ENSAPLP00000016247, ENSAPLP00000006303, ENSAPLP00000001822 |
| 92 | NOD-like receptor signaling pathway | ENSAPLP00000014548 |
| 93 | Olfactory transduction | ENSAPLP00000016135 |
| 94 | Mineral absorption | ENSAPLP00000015679 |
| 95 | N-Glycan biosynthesis | ENSAPLP00000003935 |
| 96 | Ovarian steroidogenesis | ENSAPLP00000016135 |
| 97 | Bacterial invasion of epithelial cells | ENSAPLP00000005099, ENSAPLP00000012559, ENSAPLP00000009880 |
| 98 | MicroRNAs in cancer | ENSAPLP00000014466, ENSAPLP00000013972, ENSAPLP00000003219 |
| 99 | Thyroid hormone signaling pathway | ENSAPLP00000016135, ENSAPLP00000009880 |
| 100 | Aldosterone synthesis and secretion | ENSAPLP00000016135 |
| 101 | mTOR signaling pathway | ENSAPLP00000004439 |
| 102 | Hematopoietic cell lineage | ENSAPLP00000011291 |
| 103 | Insulin secretion | ENSAPLP00000016135 |
| 104 | HTLV-I infection | ENSAPLP00000013416, ENSAPLP00000016135, ENSAPLP00000008934 |
| 105 | Galactose metabolism | ENSAPLP00000000648 |
| 106 | Arachidonic acid metabolism | ENSAPLP00000001822 |
| 107 | Wnt signaling pathway | ENSAPLP00000016135, ENSAPLP00000002426 |
| 108 | Leishmaniasis | ENSAPLP00000011291 |
| 109 | Glycine, serine and threonine metabolism | ENSAPLP00000004066 |
| 110 | Renin secretion | ENSAPLP00000016135 |
| 111 | Toxoplasmosis | ENSAPLP00000000447, ENSAPLP00000011738 |
| 112 | cAMP signaling pathway | ENSAPLP00000016135, ENSAPLP00000013090 |
| 113 | beta-Alanine metabolism | ENSAPLP00000004066 |
| 114 | Prolactin signaling pathway | ENSAPLP00000012915 |
| 115 | NF-kappa B signaling pathway | ENSAPLP00000011291 |
| 116 | Starch and sucrose metabolism | ENSAPLP00000010189 |
| 117 | Morphine addiction | ENSAPLP00000016135 |
| 118 | VEGF signaling pathway | ENSAPLP00000004050 |
| 119 | Rheumatoid arthritis | ENSAPLP00000011291 |
| 120 | Apoptosis (no map in kegg database) | ENSAPLP00000016135 |
| 121 | Dopaminergic synapse | ENSAPLP00000016135, ENSAPLP00000012915 |
| 122 | GABAergic synapse | ENSAPLP00000016135 |
| 123 | Parkinson's disease | ENSAPLP00000016135, ENSAPLP00000009300, ENSAPLP00000012915 |
| 124 | cGMP-PKG signaling pathway | ENSAPLP00000005411, ENSAPLP00000013090 |
| 125 | B cell receptor signaling pathway | ENSAPLP00000011291 |
| 126 | Long-term potentiation | ENSAPLP00000016135 |
| 127 | Pancreatic secretion | ENSAPLP00000002717 |
| 128 | Inflammatory mediator regulation of TRP channels | ENSAPLP00000016135 |
| 129 | Central carbon metabolism in cancer | ENSAPLP00000005784 |
| 130 | TNF signaling pathway | ENSAPLP00000013972 |
| 131 | Retrograde endocannabinoid signaling | ENSAPLP00000016135 |
| 132 | Protein processing in endoplasmic reticulum | ENSAPLP00000000447, ENSAPLP00000014548, ENSAPLP00000003935 |
| 133 | Natural killer cell mediated cytotoxicity | ENSAPLP00000011291 |
| 134 | Glutathione metabolism | ENSAPLP00000001822 |
| 135 | Fc epsilon RI signaling pathway | ENSAPLP00000011291 |
| 136 | Prostate cancer | ENSAPLP00000014548 |
| 137 | Salivary secretion | ENSAPLP00000016135 |
| 138 | Arginine and proline metabolism | ENSAPLP00000010692 |
| 139 | Glutamatergic synapse | ENSAPLP00000016135 |
| 140 | Ras signaling pathway | ENSAPLP00000016135, ENSAPLP00000003083 |
| 141 | Melanogenesis | ENSAPLP00000016135 |
| 142 | Antigen processing and presentation | ENSAPLP00000000447 |
| 143 | Citrate cycle (TCA cycle) | ENSAPLP00000005784 |
| 144 | Circadian entrainment | ENSAPLP00000016135 |
| 145 | Cholinergic synapse | ENSAPLP00000016135 |
| 146 | Insulin resistance | ENSAPLP00000010189 |
| 147 | Pyruvate metabolism | ENSAPLP00000005784 |
| 148 | Serotonergic synapse | ENSAPLP00000016135 |
| 149 | Cell adhesion molecules (CAMs) | ENSAPLP00000009011 |
| 150 | RNA degradation | ENSAPLP00000014331 |
| 151 | Peroxisome | ENSAPLP00000006873 |
| 152 | Sphingolipid signaling pathway | ENSAPLP00000007794 |
| 153 | AMPK signaling pathway | ENSAPLP00000010780 |
| 154 | Phospholipase D signaling pathway | ENSAPLP00000011291 |
| 155 | Shigellosis | ENSAPLP00000009880 |
| 156 | Glycolysis / Gluconeogenesis | ENSAPLP00000005784 |
| 157 | Alzheimer's disease | ENSAPLP00000009300, ENSAPLP00000011743 |
| 158 | Fc gamma R-mediated phagocytosis | ENSAPLP00000011291 |
| 159 | Ubiquitin mediated proteolysis | ENSAPLP00000008934 |
| 160 | Axon guidance | ENSAPLP00000009975 |
| 161 | Tuberculosis | ENSAPLP00000011291 |
| 162 | Chemokine signaling pathway | ENSAPLP00000016135 |
| 163 | Oxidative phosphorylation | ENSAPLP00000009300 |
| 164 | Rap1 signaling pathway | ENSAPLP00000009880 |
| 165 | RNA transport | ENSAPLP00000013416 |
| 166 | Carbon metabolism (no map in kegg database) | ENSAPLP00000005784 |
| 167 | Metabolic pathways (no map in kegg database) | ENSAPLP00000009300, ENSAPLP00000000648, ENSAPLP00000007794, ENSAPLP00000005784, ENSAPLP00000010189, ENSAPLP00000016332, ENSAPLP00000010692, ENSAPLP00000012915, ENSAPLP00000004066, ENSAPLP00000003935 |